Dexcom (DXCM)Director sold ~$25K

~$25K

Approx. value · 352 sh @ $70.33

23K

Holds after · shares reported

Traded

Mar 17, 2025

Filed

Mar 19, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REF: STK-OR-001
2. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REFs: STK-OM-001, STR-OM-001, STR-OR-001
3. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REF: STK-OE-001
4. Jan 29, 2025Insider · 5 peopleInsiders: 5 sales (~$3.6M)
5. Feb 25, 2025CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
6. Mar 10, 2025Insider · 1 personInsiders: 3 sales (~$517K)
7. Mar 12, 2025Insider · 5 peopleInsiders: 5 sales (~$5.8M)
8. Mar 17, 2025 · this disclosureInsiderDirector sold ~$25K of DXCM shares in the open market

What came next

1. Apr 7, 2025CongressDisclosed sale of DXCM — reported range $15,001 - $50,000
2. Apr 8, 2025CongressDisclosed sale of DXCM — reported range $1,001 - $15,000
3. Apr 9, 2025FDAFDA device clearance: Dexcom G7 15 Day Continuous Glucose Monitoring System
4. May 5, 2025FDARecall: Dexcom G7 iOS Application, Ref: SW12300 used in conjunction with the Dexcom G7 Continuous Glucose Monitoring (CGM) system
5. May 8, 2025CongressDisclosed purchase of DXCM — reported range $15,001 - $50,000
6. May 12, 2025FDARecall: Dexcom One+ Continuous Glucose Monitoring System, SKU(Part Number): STK-D7-013 (MT28285-1), STK-D7-014 (MT28285-1), STK-D7-103 (MT28285-2)
7. May 12, 2025FDARecall: Dexcom One Continuous Glucose Monitoring System, SKUs(Part Number): STK-DO-006 (MT27409-1), STK-DO-013 (MT27409-1), STK-DO-103 (MT27409-2), STK-DO-109 (MT27409…
8. May 12, 2025FDARecall: Dexcom G6 Glucose Receiver, SKUs (Part Number): STK-FM-001 (MT27408-1) & STK-FR-001 (MT27408-1)
9. May 12, 2025FDARecall: Dexcom G7 Glucose Receiver, SKUs (part number): STK-AT-011(MT26403-0), STK-AT-012 (MT26403-0), STK-AT-013 (MT26403-0), STK-GT-001 (MT26403-1), STK-GT-008 (MT26…
10. May 12, 2025CongressDisclosed sale of DXCM — reported range $15,001 - $50,000
11. May 15, 2025CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
12. May 23, 2025InsiderOfficer sold ~$843K of DXCM shares in the open market
13. May 27, 2025InsiderOfficer sold ~$526K of DXCM shares in the open market
14. Jun 13, 2025InsiderDirector sold ~$214K of DXCM shares in the open market
15. Jun 16, 2025Insider · 3 peopleInsiders: 3 sales (~$574K)
16. Jun 26, 2025InsiderOfficer sold ~$125K of DXCM shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Bridgette P Heller, Director

• SEC Form 4 at Dexcom (DXCM)Aug 13, 2026
• SEC Form 4 at Dexcom (DXCM)May 14, 2026
• SEC Form 4 at Dexcom (DXCM)Feb 17, 2026
• SEC Form 4 at Dexcom (DXCM)Nov 12, 2025
• SEC Form 4 at Dexcom (DXCM)Dec 17, 2024

The full history of Bridgette P Heller, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dexcom

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026

Everything OQRO holds on this company is on its DXCM page.